| abstract |
The present invention relates to chimeric antigen receptors that target IL13R α 2, nucleic acid molecules encoding the chimeric antigen receptors, vectors comprising the nucleic acid molecules, and immune effector cells (e.g., T cells, NK cells) engineered to express the chimeric antigen receptors. The invention also relates to the use of said engineered immune effector cells for the treatment of diseases associated with the expression of IL13R α 2, e.g., gliomas. |